HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 10 (October)

1. Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women.
   Obstet Gynecol, 108(4): 953-60. [Abstract] [Full-text]
2. What is the achievable effectiveness of the India AIDS Initiative intervention among female sex workers under target coverage? Model projections from southern India.
   Sex Transm Infect, 82(5): 372-80. [Abstract] [Full-text]
3. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.
   Virology, 354(1): 15-27. [Abstract] [Full-text]
4. Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques.
   Virology, 354(1): 192-206. [Abstract] [Full-text]
5. Reactivation of ancestral strains of HIV-1 in the gp120 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption.
   Virology, 354(1): 35-47. [Abstract] [Full-text]
6. A prospective study assessing the effects of introducing the female condom in a sex worker population in Mombasa, Kenya.
   Sex Transm Infect, 82(5): 397-402. [Abstract] [Full-text]
7. Estimation of the sexual transmission of HIV in Kenya and Uganda on the trans-Africa highway: the continuing role for prevention in high risk groups.
   Sex Transm Infect, 82(5): 368-71. [Abstract] [Full-text]
8. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast.
   Pediatrics, 118(4): e1071-7. [Abstract] [Full-text]
9. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
   Clin Pharmacol Ther, 80(4): 307-18. [Abstract] [Full-text]
10. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions.
    Proc Natl Acad Sci U S A, 103(40): 14947-52. [Abstract] [Full-text]
11. Establishment of a rodent model of HIV-associated sensory neuropathy.
    J Neurosci, 26(40): 10299-304. [Abstract] [Full-text]
12. Generation of simian-tropic HIV-1 by restriction factor evasion.
    Science, 314(5796): 95. [Abstract] [Full-text]
13. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients.
    Clin Infect Dis, 43(9): 1209-12. [Abstract] [Full-text]
14. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
    Clin Infect Dis, 43(9): 1198-205. [Abstract] [Full-text]
15. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study.
    Lancet, 368(9543): 1254-9. [Abstract] [Full-text]
16. Assessment of retinal function in patients with HIV without infectious retinitis by multifocal electroretinogram and automated perimetry.
    Retina, 26(8): 928-34. [Abstract] [Full-text]
17. Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus.
    J Gen Virol, 87: 3385-92. [Abstract] [Full-text]
18. Structure/function mapping of amino acids in the N-terminal zinc finger of the human immunodeficiency virus type 1 nucleocapsid protein: residues responsible for nucleic acid helix destabilizing activity.
    Biochemistry, 45(41): 12617-28. [Abstract] [Full-text]
19. Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands.
    Semin Immunol, 18(6): 387-403. [Abstract] [Full-text]
20. Bifunctional recombinant fusion proteins for rapid detection of antibodies to both HIV-1 and HIV-2 in whole blood.
    BMC Biotechnol, 6: 39. [Abstract] [Full-text]
21. A high-throughput drug screening system for HIV-1 transcription inhibitors.
    J Biomol Screen, 11(7): 807-15. [Abstract] [Full-text]
22. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Biochem J, 399(3): 483-91. [Abstract] [Full-text]
23. Septic arthritis in patients with human immunodeficiency virus.
    Clin Orthop Relat Res, 451: 46-9. [Abstract] [Full-text]
24. Genomics meets HIV-1.
    Nat Rev Microbiol, 4(11): 865-73. [Abstract] [Full-text]
25. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient.
    J Infect, 53(5): e215-8. [Abstract] [Full-text]
26. Serosurveillance of acute Mycoplasma pneumoniae infection among HIV infected patients with pulmonary complaints in Chennai, Southern India.
    J Infect, 53(5): 325-30. [Abstract] [Full-text]
27. Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort.
    BMC Infect Dis, 6: 146. [Abstract] [Full-text]
28. Optimizing resource allocation in United States AIDS drug assistance programs.
    Clin Infect Dis, 43(10): 1357-64. [Abstract] [Full-text]
29. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Clin Infect Dis, 43(10): 1347-56. [Abstract] [Full-text]
30. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Clin Infect Dis, 43(10): 1337-46. [Abstract] [Full-text]
31. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
    Clin Infect Dis, 43(10): 1329-36. [Abstract] [Full-text]
32. An essential role for LEDGF/p75 in HIV integration.
    Science, 314(5798): 461-4. [Abstract] [Full-text]
33. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru.
    J Infect Dis, 194(10): 1459-66. [Abstract] [Full-text]
34. HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations.
    J Infect Dis, 194(10): 1450-8. [Abstract] [Full-text]
35. The natural history of antibody responses to Cryptosporidium parasites in men at high risk of HIV infection.
    J Infect Dis, 194(10): 1428-37. [Abstract] [Full-text]
36. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.
    BMC Infect Dis, 6: 150. [Abstract] [Full-text]
37. Single DNA molecule stretching measures the activity of chemicals that target the HIV-1 nucleocapsid protein.
    Anal Biochem, 358(2): 159-70. [Abstract] [Full-text]
38. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users.
    Neurology, 67(8): 1486-9. [Abstract] [Full-text]
39. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
    Virology, 355(1): 1-5. [Abstract] [Full-text]
40. Characterization of the human chemerin receptor--ChemR23/CMKLR1--as co-receptor for human and simian immunodeficiency virus infection, and identification of virus-binding receptor domains.
    Virology, 355(1): 6-17. [Abstract] [Full-text]
41. Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation.
    Epidemiol Infect, 134(6): 1345-52. [Abstract] [Full-text]
42. Impact of immigration and HIV infection on tuberculosis incidence in an area of low tuberculosis prevalence.
    Epidemiol Infect, 134(6): 1353-9. [Abstract] [Full-text]
43. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Lancet, 368(9546): 1503-15. [Abstract] [Full-text]
44. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse.
    J Clin Oncol, 24(31): 5005-9. [Abstract] [Full-text]
45. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    J Med Virol, 78(12): 1537-41. [Abstract] [Full-text]
46. Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain.
    J Med Virol, 78(12): 1520-8. [Abstract] [Full-text]
47. Significant link between sCD30 changes and HIV viremia in patients treated with HAART.
    J Med Virol, 78(12): 1513-9. [Abstract] [Full-text]
48. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain.
    J Med Virol, 78(12): 1599-608. [Abstract] [Full-text]
49. Serotyping and genotyping of HIV-1 infection in residents of Khayelitsha, Cape Town, South Africa.
    J Med Virol, 78(12): 1529-36. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.